Targeting Genetic Drivers of Rare Genitourinary Cancers

Video

This video reviews new studies examining the genetic drivers of three rare genitourinary cancers: von Hippel-Lindau disease, advanced papillary renal cell carcinoma, and penile cancer.

In this video, Guru Sonpavde, MD, of the University of Alabama at Birmingham Comprehensive Cancer Center, reviews three new studies involving rare genitourinary cancers: a phase II study of pazopanib in von Hippel-Lindau disease (abstract 4516), a comprehensive genomic profiling of advanced papillary renal cell carcinoma (abstract 4517), and a multiregion sequencing of penile cancer that revealed actionable mutations (abstract 4519).

Sonpavde was the discussant during a poster discussion session on the identification and targeting of genetic drivers of rare genitourinary cancers, which featured these three studies, at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held last month in Chicago.

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Related Content